Chemical Biology Program
The Heeseon An Lab
Human cells orchestrate up to ~20,687 proteins to maintain cell growth and survival. Upon environmental change, cells dynamically remodel their proteomic landscape by two simultaneous processes: enhancing the synthesis of proteins that respond to the altered cellular conditions and degrading a subset of the pre-existing proteome. Any defect in this nature’s fine-tuned system hampers regulated cell growth as exemplified by cancer and neurodegenerative disorders. To fully understand the underlying pathology of the dysregulated proteostasis system, Heeseon An’s lab studies the regulatory mechanisms of protein translation and degradation processes in health and disease. Importantly, we develop chemical, biological, and proteomics tools to enable quantitative analyses of the cell biological events.
Jordan VN, Ordureau A, An H* (2023) Identifying E3 ligase substrates with quantitative degradation proteomics. Chembiochem. Online ahead of print.
An H#, Ordureau A#, Koerner M, Paulo JA, Harper JW (2020) Systematic quantitative analysis of ribosome inventory during nutrient stress. Nature, 583, 303-309. # equal contribution
An H, Harper, JW (2020) Ribosome Abundance Control Via the Ubiquitin-Proteasome System and Autophagy. J. Mol. Biol. 432, 170-184, review article
An H, Ordureau A, Paulo JA, Shoemaker CJ, Denic V, Harper JW (2019) TEX264 Is an Endoplasmic Reticulum-Resident ATG8-Interacting Protein Critical for ER Remodeling during Nutrient Stress. Molecular Cell, 74, 891-908.
An H, Harper JW (2018) Systematic analysis of ribophagy in human cells reveals bystander flux during selective autophagy. Nat. Cell Biol., 20, 135-143.
Heeseon An, PhD
- Heeseon An’s lab studies protein degradation in health and disease using chemical, biological, and proteomics tools.
- BS and MS, Chemistry, Seoul National University
- PhD, Chemistry, Northwestern University
- Postdoc, Cell Biology, Harvard Medical School
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Heeseon An discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.